1Guidelines Subxommittee.1999 WorldHealth Organizatiou-International Society of Hypertension Guidelines for the Mana-gementof Hyertension. J Hypertersion.1999;17:151-183.
2Weber MA.Clinical experience with the angiotensin Ⅱ receptor antagonistlosartan:a preliminary report. Am J Hypertens.1992;5:247S-251S.
3De Gasparo M,Siragy HM.The AT2 recepor:fact,fancy and fantasy. RegulatoryPeptides.1999;81:11-24.
4Criscone L,Gradley WA,Buehlmayerp,et al.Valsartan:preclinical and clinical profileof an antihypertensive angiotensin Ⅱ antagonist. Cardiovasc Drug Rev.1995;13:230-250.
5Markham A,Goa KL.Valsartan.A review of its pharmacology and Therapeutic use inessential hypertension. Drugs.1997;54:299-311.
6Griscione L,De Gasparo M,Buhlmayer P,et al.Pharmacological profile ofvalsartan:apotent,orally active,nonpeptide antagonist of the angiotensin Ⅱ AT1-receptorsubtype. Br J pharmacot.1993;110:761-771.
7De Grasparo M,Whitebread S.Binding of valsartan to mammalian angiotensin AT1receptors. Regul Pept.1995;59:303-311.
8Muller P,Flesch G,De Gasparo M et al.Pharmacokinetics and pharmacodynamic effect ofthe angiotensin Ⅱ antagonist valsartan at steady state in healthy,normotensive subjects.Eur J Clin Pharmacol.1997;52:441-449.
9JR Benz,HR Black,A Graff et al.Valsartan and hydrochlorothiazide in patients withessential hypertension.A multiple dose,double-blind,placebo controlled trial comparingcombination therapy with monotherapy. J Human Hypertension.1998;12:861-866.
10James pool,Suzanne Oparil,Thomas Hedner et al.Dose-Responsive AntihypertensiveEfficacy of valsartan,a New Angiotensin Ⅱ-Receptor Blocker. ClinicalTherapeutics.1998;20(6):1106-1114
